BJ Bioscience, Inc., a China-based biotech company, announced on Monday that it has signed a clinical trial collaboration and supply agreement with United States-based Merck & Co., Inc (MSD).
The partnership is intended to enable an assessment of the safety and efficacy of BJ-001, a tumour-targeting IL-15 fusion protein, in combination with MSD's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in an ongoing Phase one clinical trial.
BJ Bioscience is to assess the combination of BJ-001 and KEYTRUDA as part of the company's ongoing trial in subjects with locally advanced/metastatic solid tumours. During this trial, the product is to be studied as monotherapy or in combination with KEYTRUDA, for safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. BJ-001 has showcased tolerable safety profiles, favourable PK/PD profiles, and encouraging preliminary efficacy outcome in monotherapy dose escalation cohorts.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval